Literature DB >> 20580392

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Jae-Min Song1, Jaber Hossain, Dae-Goon Yoo, Aleksandr S Lipatov, C Todd Davis, Fu-Shi Quan, Li-Mei Chen, Robert J Hogan, Ruben O Donis, Richard W Compans, Sang-Moo Kang.   

Abstract

We generated influenza virus-like particles (VLPs) containing the wild type (WT) H5 hemagglutinin (HA) from A/Viet Nam/1203/04 virus or a mutant H5 HA with a deletion of the multibasic cleavage motif. VLPs containing mutant H5 HA were found to be as immunogenic as VLPs containing WT HA. A single intramuscular vaccination with either type of H5 VLPs provided complete protection against lethal challenge. In contrast, the recombinant H5 HA vaccine was less immunogenic and vaccination even with a 5 fold higher dose did not induce protective immunity. VLP vaccines were superior to the recombinant HA in inducing T helper type 1 immune responses, hemagglutination inhibition titers, and antibody secreting cells, which significantly contribute to inducing protective immunity after a single dose vaccination. This study provides insights into the potential mechanisms of improved immunogenicity by H5 VLP vaccines as an approach to improve the protective efficacy against potential pandemic viruses. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20580392      PMCID： PMC2925114          DOI： 10.1016/j.virol.2010.05.034

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  63 in total

1.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

Authors:  J J Treanor; B E Wilkinson; F Masseoud; J Hu-Primmer; R Battaglia; D O'Brien; M Wolff; G Rabinovich; W Blackwelder; J M Katz
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

2.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

Review 3.  Modulating vaccine responses with dendritic cells and Toll-like receptors.

Authors:  Bali Pulendran
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

4.  Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections.

Authors:  V C Huber; J M Lynch; D J Bucher; J Le; D W Metzger
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

5.  Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.

Authors:  N Hehme; H Engelmann; W Künzel; E Neumeier; R Sänger
Journal:  Med Microbiol Immunol       Date:  2002-10-19       Impact factor: 3.402

6.  Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

Authors:  Iain Stephenson; Karl G Nicholson; Reinhardt Glück; Robert Mischler; Robert W Newman; Abraham M Palache; Neville Q Verlander; Fiona Warburton; John M Wood; Maria C Zambon
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

7.  Origins of the new influenza A(H1N1) virus: time to take action.

Authors:  G M Nava; M S Attene-Ramos; J K Ang; M Escorcia
Journal:  Euro Surveill       Date:  2009-06-04

8.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.

Authors:  Ron A M Fouchier; Peter M Schneeberger; Frans W Rozendaal; Jan M Broekman; Stiena A G Kemink; Vincent Munster; Thijs Kuiken; Guus F Rimmelzwaan; Martin Schutten; Gerard J J Van Doornum; Guus Koch; Arnold Bosman; Marion Koopmans; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

9.  Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

Authors:  Kanta Subbarao; Hualan Chen; David Swayne; Louise Mingay; Ervin Fodor; George Brownlee; Xiyan Xu; Xiuhua Lu; Jacqueline Katz; Nancy Cox; Yumiko Matsuoka
Journal:  Virology       Date:  2003-01-05       Impact factor: 3.616

10.  Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

Authors:  R J Webby; D R Perez; J S Coleman; Y Guan; J H Knight; E A Govorkova; L R McClain-Moss; J S Peiris; J E Rehg; E I Tuomanen; R G Webster
Journal:  Lancet       Date:  2004-04-03       Impact factor: 79.321
View more
  56 in total

1.  DNA vaccination in the skin using microneedles improves protection against influenza.

Authors:  Jae-Min Song; Yeu-Chun Kim; Eunju O; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

2.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus.

Authors:  Jae-Min Song; Nico Van Rooijen; Jadranka Bozja; Richard W Compans; Sang-Moo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  Mucosal vaccination against tuberculosis using inert bioparticles.

Authors:  Rajko Reljic; Laura Sibley; Jen-Min Huang; Ilaria Pepponi; Andreas Hoppe; Huynh A Hong; Simon M Cutting
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

Review 4.  Progress in developing virus-like particle influenza vaccines.

Authors:  Fu-Shi Quan; Young-Tae Lee; Ki-Hye Kim; Min-Chul Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2016-05-05       Impact factor: 5.217

5.  Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination.

Authors:  Eunju O; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Yu-Na Lee; Jae-Min Song; Young-Man Kwon; Min-Chul Kim; Daniel R Perez; Sang-Moo Kang
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

6.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

7.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

8.  CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.

Authors:  Young-Tae Lee; Eun-Ju Ko; Youri Lee; Yu-Na Lee; Zhen Bian; Yuan Liu; Sang-Moo Kang
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

9.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

10.  Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.

Authors:  Young-Man Kwon; Hye Suk Hwang; Jong Seok Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Jae-Min Song; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.